Advanced Biomed Inc. Common Stock (ADVB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Advanced Biomed Inc. Common Stock (ADVB) has a cash flow conversion efficiency ratio of -0.024x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.89K) by net assets ($288.07K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Advanced Biomed Inc. Common Stock net asset quality index to measure how much of total assets are equity-financed.
Advanced Biomed Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Advanced Biomed Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ADVB cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Advanced Biomed Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Advanced Biomed Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wahana Pronatural
JK:WAPO
|
0.002x |
|
Energy Development Company Limited
NSE:ENERGYDEV
|
-5.422x |
|
XTL Biopharmaceuticals Ltd ADR
NASDAQ:XTLB
|
-0.369x |
|
FGI Industries Ltd
NASDAQ:FGI
|
-0.023x |
|
NEXE Innovations Inc
V:NEXE
|
-0.026x |
|
Talisman Mining Ltd
AU:TLM
|
-0.083x |
|
Renoworks Software Inc
V:RW
|
-1.842x |
|
BRADDA HEAD LITHIUM O.N.
F:8CD1
|
0.059x |
Annual Cash Flow Conversion Efficiency for Advanced Biomed Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Advanced Biomed Inc. Common Stock from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see Advanced Biomed Inc. Common Stock stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $3.48 Million | $-181.46K | -0.052x | +95.92% |
| 2024-06-30 | $1.66 Million | $-2.13 Million | -1.278x | +43.68% |
| 2023-06-30 | $1.31 Million | $-2.96 Million | -2.270x | -968.95% |
| 2022-06-30 | $3.49 Million | $-741.45K | -0.212x | +56.26% |
| 2021-06-30 | $976.24K | $-473.98K | -0.486x | -- |
About Advanced Biomed Inc. Common Stock
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagul… Read more